Skip to main content

HomeResearchOxyntomodulin

CategoryFat Loss
SafetyMedium Risk
StatusResearch Only

Oxyntomodulin

OXM · glicentin-related pancreatic peptide

CategoryFat Loss
Half-life
Routesubcutaneous, intravenous
RiskMedium Risk
ProvidersNone listed

About Oxyntomodulin

Dual GLP-1/glucagon receptor agonist. GLP-1 component suppresses appetite; glucagon component increases energy expenditure and fatty acid oxidation. Net effect is reduced caloric intake and elevated metabolic rate.

An endogenous peptide produced in the gut that activates both GLP-1 and glucagon receptors. Dual receptor activation produces appetite suppression plus increased energy expenditure — a combination not achievable with GLP-1 agonists alone.

Research Areas

appetite suppressionenergy expenditurefat oxidation

Regulatory & Evidence

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Review contraindications and administration guidelines before use.

Regulatory Status

Availability Status
Research Only

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Safety Notes

Medium Risk

Moderate risk profile. Review all reported considerations carefully before use.

Reported contraindications & considerations

Thyroid ConditionKidney Or Liver ConditionPregnant Or Nursing

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Where to Find Oxyntomodulin

Coverage expanding

No verified providers currently list Oxyntomodulin. Get notified when one does, or explore providers carrying similar peptides in the Fat Loss category.

Frequently Asked Questions — Oxyntomodulin

An endogenous peptide produced in the gut that activates both GLP-1 and glucagon receptors. Dual receptor activation produces appetite suppression plus increased energy expenditure — a combination not achievable with GLP-1 agonists alone.

appetite suppression, energy expenditure, fat oxidation.

Newsletter

The Peptide Research Digest

New providers, emerging stacks, and research developments — weekly.

No spam. Unsubscribe anytime. Privacy policy.